Role of Everolimus in Providing Protection from CMV Infection after Transplant by Improving T-cell Specific Immunity

García‐Romero, Elena; Díez-López, Carles; Olivella, A.; Roca, Josep; Bestard, Oriol; Sabé, Núria; Manito, Nicolás; González‐Costello, José

doi:10.1016/j.healun.2021.01.1981

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Everolimus replaced MMF in 47% of our patients and only one experienced CMV recurrence. As in kidney transplantation, where there seems to be a beneficial impact on immune compartments other than CD8+ T-cells, 12 switching to everolimus might be considered in CMV-experiencing HTR, 14 especially if ATG is used for induction.…”

Section: Discussionmentioning

confidence: 99%

Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study

Sermet,

Goeminne,

Hantz

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

BackgroundRecurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.MethodsThis observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.ResultsAmong the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.ConclusionIn the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%